These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1830249)

  • 1. Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma.
    Licht JD; Gonin R; Antman KH
    Cancer Chemother Pharmacol; 1991; 28(3):223-5. PubMed ID: 1830249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of metastatic malignant melanoma with trimetrexate: a phase II study.
    Odujinrin O; Goldberg D; Doroshow J; Leong L; Margolin K; Grove W; Carr B; Akman S
    Med Pediatr Oncol; 1990; 18(1):49-52. PubMed ID: 2136764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections.
    Jolivet J; Landry L; Pinard MF; McCormack JJ; Tong WP; Eisenhauer E
    Cancer Chemother Pharmacol; 1987; 20(2):169-72. PubMed ID: 2959389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of 10-EDAM in advanced soft tissue sarcoma. A study of the Canadian Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group.
    Knowling M; Bramwell V; Eisenhauer E; Boos G; Bodurtha A; Quirt I
    Ann Oncol; 1994 Oct; 5(8):766-8. PubMed ID: 7826912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer.
    Kris MG; D'Acquisto RW; Gralla RJ; Burke MT; Marks LD; Fanucchi MP; Heelan RT
    Am J Clin Oncol; 1989 Feb; 12(1):24-6. PubMed ID: 2536213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlates of severe or life-threatening toxic effects from trimetrexate.
    Grem JL; Ellenberg SS; King SA; Shoemaker DD
    J Natl Cancer Inst; 1988 Oct; 80(16):1313-8. PubMed ID: 2971817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study.
    Iscoe NA; Eisenhauer EA; Bodurtha AJ
    Invest New Drugs; 1990 Feb; 8(1):121-3. PubMed ID: 2140563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypersensitivity reactions to trimetrexate.
    Grem JL; King SA; Costanza ME; Brown TD
    Invest New Drugs; 1990 May; 8(2):211-4. PubMed ID: 2143501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
    Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric phase I trial and pharmacokinetic study of trimetrexate.
    Balis FM; Patel R; Luks E; Doherty KM; Holcenberg JS; Tan C; Reaman GH; Belasco J; Ettinger LJ; Zimm S
    Cancer Res; 1987 Sep; 47(18):4973-6. PubMed ID: 2957048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion.
    Bishop JF; Raghavan D; Olver IN; Reece P; Morris R; Friedlander ML
    Cancer Chemother Pharmacol; 1989; 24(4):246-50. PubMed ID: 2526692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma.
    Ajani JA; Abbruzzese JL; Faintuch JS; Patt YZ; Boman BM; Jackson DE; Levin B; Krakoff IH
    Cancer Invest; 1990; 8(6):619-21. PubMed ID: 2149834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
    Grochow LB; Noe DA; Ettinger DS; Donehower RC
    Cancer Chemother Pharmacol; 1989; 24(5):314-20. PubMed ID: 2758561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer.
    Leiby JM
    Semin Oncol; 1988 Apr; 15(2 Suppl 2):27-31. PubMed ID: 2966983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimetrexate as a single agent in patients with advanced head and neck cancer.
    Robert F
    Semin Oncol; 1988 Apr; 15(2 Suppl 2):22-6. PubMed ID: 2966982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.
    Allegra CJ; Jenkins J; Weiss RB; Balis F; Drake JC; Brooks J; Thomas R; Curt GA
    Invest New Drugs; 1990 May; 8(2):159-66. PubMed ID: 2143500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I studies of trimetrexate using single and weekly dose schedules.
    Huan SD; Legha SS; Raber MN; Krakoff IH
    Invest New Drugs; 1991 May; 9(2):199-206. PubMed ID: 1831442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
    Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
    Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
    Stewart JA; McCormack JJ; Tong W; Low JB; Roberts JD; Blow A; Whitfield LR; Haugh LD; Grove WR; Lopez AJ
    Cancer Res; 1988 Sep; 48(17):5029-35. PubMed ID: 2970294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.